Janus Activated Kinase inhibition in Myelofibrosis.
Indian J Cancer
;
2012 Jul-Sept; 49(3): 260-265
Article
in English
| IMSEAR
| ID: sea-144583
ABSTRACT
Janus Activated Kinase (JAK) 2 plays an important role in the pathogenesis of myelofibrosis (MF). Ruxolitinib (INCB018424, Jakafi) is a potent dual JAK1 and JAK2 inhibitor. In November 2011, it became approved by the US FDA for the treatment of intermediate or high-risk MF. This review shall outline the role of Ruxolitinib in the current management of MF and its potential future.
Full text:
Available
Index:
IMSEAR (South-East Asia)
Main subject:
Pyrazoles
/
Humans
/
Janus Kinase 1
/
Janus Kinase 2
/
Primary Myelofibrosis
Language:
English
Journal:
Indian J Cancer
Year:
2012
Type:
Article
Similar
MEDLINE
...
LILACS
LIS